How much revenue did Kyung Nam Pharm Co generate this year?
Kyung Nam Pharm Co has achieved a revenue of 60.79 B KRW this year.
Kyung Nam Pharm Co Revenue 2025
Kyung Nam Pharm Co Revenue
60.79 B KRW
Ticker
053950.KQ
ISIN
KR7053950002
In 2025, Kyung Nam Pharm Co's sales reached 60.79 B KRW, a 2.51% difference from the 59.3 B KRW sales recorded in the previous year.
The Kyung Nam Pharm Co Revenue history
| YEAR | REVENUE (undefined KRW) | GROSS MARGIN (%) |
|---|---|---|
| 2024 | 60.79 | 28,33 |
| 2023 | 59.3 | 32,54 |
| 2022 | 59 | 27,79 |
| 2021 | 64.62 | 32,61 |
| 2020 | 70.95 | 40,13 |
| 2019 | 44.81 | 37,59 |
| 2018 | 41.43 | 40,25 |
| 2017 | 40.17 | 42,60 |
| 2016 | 39.76 | 43,87 |
| 2015 | 39.09 | 49,57 |
| 2014 | 36.01 | 47,22 |
| 2013 | 32.76 | 46,53 |
| 2012 | 40.3 | 49,29 |
| 2011 | 44.41 | 38,85 |
| 2010 | 52.44 | 44,62 |
| 2009 | 55.73 | 49,45 |
| 2008 | 51.37 | 61,03 |
| 2007 | 31.29 | 52,76 |
| 2006 | 33.11 | 5,82 |
| 2005 | 31.73 | 8,39 |
Kyung Nam Pharm Co Revenue, EBIT, Net Income KR7053950002 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Kyung Nam Pharm Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kyung Nam Pharm Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kyung Nam Pharm Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Kyung Nam Pharm Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Kyung Nam Pharm Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Kyung Nam Pharm Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kyung Nam Pharm Co’s growth potential.
Kyung Nam Pharm Co Revenue, EBIT and net profit per share
| Date | Kyung Nam Pharm Co Revenue | Kyung Nam Pharm Co EBIT | Kyung Nam Pharm Co Net Income |
|---|---|---|---|
| 2024 | 60.79 B undefined | -942.82 M undefined | 10.08 B undefined |
| 2023 | 59.3 B undefined | -3.59 B undefined | -21 B undefined |
| 2022 | 59 B undefined | -3.39 B undefined | -7.83 B undefined |
| 2021 | 64.62 B undefined | -7.73 B undefined | -3.41 B undefined |
| 2020 | 70.95 B undefined | 2.23 B undefined | -5.49 B undefined |
| 2019 | 44.81 B undefined | -3.15 B undefined | -4.55 B undefined |
| 2018 | 41.43 B undefined | -841 M undefined | 3.72 B undefined |
| 2017 | 40.17 B undefined | 3.73 B undefined | -3.48 B undefined |
| 2016 | 39.76 B undefined | 5.34 B undefined | 130 M undefined |
| 2015 | 39.09 B undefined | 6.83 B undefined | 2.11 B undefined |
| 2014 | 36.01 B undefined | 3.65 B undefined | 581 M undefined |
| 2013 | 32.76 B undefined | 525 M undefined | -16.61 B undefined |
| 2012 | 40.3 B undefined | 4.63 B undefined | 5 M undefined |
| 2011 | 44.41 B undefined | 2.05 B undefined | -3.73 B undefined |
| 2010 | 52.44 B undefined | 656 M undefined | -4.03 B undefined |
| 2009 | 55.73 B undefined | 4.84 B undefined | -1.28 B undefined |
| 2008 | 51.37 B undefined | 13.81 B undefined | 994 M undefined |
| 2007 | 31.29 B undefined | -58.75 B undefined | -65.66 B undefined |
| 2006 | 33.11 B undefined | -2.69 B undefined | -3.52 B undefined |
| 2005 | 31.73 B undefined | -1.75 B undefined | -369 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 31.73 B KRW | -1.75 B KRW | -369 M KRW |
| 2006 | 33.11 B KRW | -2.69 B KRW | -3.52 B KRW |
| 2007 | 31.29 B KRW | -58.75 B KRW | -65.66 B KRW |
| 2008 | 51.37 B KRW | 13.81 B KRW | 994 M KRW |
| 2009 | 55.73 B KRW | 4.84 B KRW | -1.28 B KRW |
| 2010 | 52.44 B KRW | 656 M KRW | -4.03 B KRW |
| 2011 | 44.41 B KRW | 2.05 B KRW | -3.73 B KRW |
| 2012 | 40.3 B KRW | 4.63 B KRW | 5 M KRW |
| 2013 | 32.76 B KRW | 525 M KRW | -16.61 B KRW |
| 2014 | 36.01 B KRW | 3.65 B KRW | 581 M KRW |
| 2015 | 39.09 B KRW | 6.83 B KRW | 2.11 B KRW |
| 2016 | 39.76 B KRW | 5.34 B KRW | 130 M KRW |
| 2017 | 40.17 B KRW | 3.73 B KRW | -3.48 B KRW |
| 2018 | 41.43 B KRW | -841 M KRW | 3.72 B KRW |
| 2019 | 44.81 B KRW | -3.15 B KRW | -4.55 B KRW |
| 2020 | 70.95 B KRW | 2.23 B KRW | -5.49 B KRW |
| 2021 | 64.62 B KRW | -7.73 B KRW | -3.41 B KRW |
| 2022 | 59 B KRW | -3.39 B KRW | -7.83 B KRW |
| 2023 | 59.3 B KRW | -3.59 B KRW | -21 B KRW |
| 2024 | 60.79 B KRW | -942.82 M KRW | 10.08 B KRW |
Kyung Nam Pharm Co stock margins KR7053950002 ·
The Kyung Nam Pharm Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kyung Nam Pharm Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kyung Nam Pharm Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Kyung Nam Pharm Co's sales revenue. A higher gross margin percentage indicates that the Kyung Nam Pharm Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Kyung Nam Pharm Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Kyung Nam Pharm Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kyung Nam Pharm Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kyung Nam Pharm Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kyung Nam Pharm Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Kyung Nam Pharm Co Margin History
| Kyung Nam Pharm Co Gross margin | Kyung Nam Pharm Co Profit margin | Kyung Nam Pharm Co EBIT margin | Kyung Nam Pharm Co Profit margin |
|---|---|---|---|
| 2024 | 28.33 % | -1.55 % | 16.58 % |
| 2023 | 32.54 % | -6.05 % | -35.41 % |
| 2022 | 27.79 % | -5.75 % | -13.27 % |
| 2021 | 32.61 % | -11.95 % | -5.28 % |
| 2020 | 40.13 % | 3.14 % | -7.74 % |
| 2019 | 37.59 % | -7.03 % | -10.15 % |
| 2018 | 40.25 % | -2.03 % | 8.98 % |
| 2017 | 42.6 % | 9.3 % | -8.66 % |
| 2016 | 43.87 % | 13.43 % | 0.33 % |
| 2015 | 49.57 % | 17.47 % | 5.4 % |
| 2014 | 47.22 % | 10.12 % | 1.61 % |
| 2013 | 46.53 % | 1.6 % | -50.7 % |
| 2012 | 49.29 % | 11.5 % | 0.01 % |
| 2011 | 38.85 % | 4.61 % | -8.39 % |
| 2010 | 44.62 % | 1.25 % | -7.69 % |
| 2009 | 49.45 % | 8.68 % | -2.3 % |
| 2008 | 61.03 % | 26.88 % | 1.93 % |
| 2007 | 52.76 % | -187.75 % | -209.85 % |
| 2006 | 5.82 % | -8.13 % | -10.63 % |
| 2005 | 8.39 % | -5.52 % | -1.16 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 8.39 % | -5.52 % | -1.16 % |
| 2006 | 5.82 % | -8.13 % | -10.63 % |
| 2007 | 52.76 % | -187.75 % | -209.85 % |
| 2008 | 61.03 % | 26.88 % | 1.93 % |
| 2009 | 49.45 % | 8.68 % | -2.3 % |
| 2010 | 44.62 % | 1.25 % | -7.69 % |
| 2011 | 38.85 % | 4.61 % | -8.39 % |
| 2012 | 49.29 % | 11.5 % | 0.01 % |
| 2013 | 46.53 % | 1.6 % | -50.7 % |
| 2014 | 47.22 % | 10.12 % | 1.61 % |
| 2015 | 49.57 % | 17.47 % | 5.4 % |
| 2016 | 43.87 % | 13.43 % | 0.33 % |
| 2017 | 42.6 % | 9.3 % | -8.66 % |
| 2018 | 40.25 % | -2.03 % | 8.98 % |
| 2019 | 37.59 % | -7.03 % | -10.15 % |
| 2020 | 40.13 % | 3.14 % | -7.74 % |
| 2021 | 32.61 % | -11.95 % | -5.28 % |
| 2022 | 27.79 % | -5.75 % | -13.27 % |
| 2023 | 32.54 % | -6.05 % | -35.41 % |
| 2024 | 28.33 % | -1.55 % | 16.58 % |
Kyung Nam Pharm Co Aktienanalyse
What does Kyung Nam Pharm Co do?
Kyung Nam Pharm Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Kyung Nam Pharm Co's Sales Figures
The sales figures of Kyung Nam Pharm Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Kyung Nam Pharm Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Kyung Nam Pharm Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Kyung Nam Pharm Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Kyung Nam Pharm Co stock
How much was the turnover of the company Kyung Nam Pharm Co compared to the previous year?
The revenue of Kyung Nam Pharm Co has increased by 2.51% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Kyung Nam Pharm Co?
The revenue of Kyung Nam Pharm Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Kyung Nam Pharm Co measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Kyung Nam Pharm Co so important for investors?
The revenue of Kyung Nam Pharm Co is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Kyung Nam Pharm Co pay?
Over the past 12 months, Kyung Nam Pharm Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kyung Nam Pharm Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of Kyung Nam Pharm Co?
The current dividend yield of Kyung Nam Pharm Co is .
When does Kyung Nam Pharm Co pay dividends?
Kyung Nam Pharm Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Kyung Nam Pharm Co?
Kyung Nam Pharm Co paid dividends every year for the past 0 years.
What is the dividend of Kyung Nam Pharm Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is Kyung Nam Pharm Co located?
Kyung Nam Pharm Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Kyung Nam Pharm Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Kyung Nam Pharm Co from 4/11/2005 amounting to 40 KRW, you needed to have the stock in your portfolio before the ex-date on 12/29/2004.
When did Kyung Nam Pharm Co pay the last dividend?
The last dividend was paid out on 4/11/2005.
What was the dividend of Kyung Nam Pharm Co in the year 2024?
In the year 2024, Kyung Nam Pharm Co distributed 0 KRW as dividends.
In which currency does Kyung Nam Pharm Co pay out the dividend?
The dividends of Kyung Nam Pharm Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Kyung Nam Pharm Co
Our stock analysis for Kyung Nam Pharm Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyung Nam Pharm Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Kyung Nam Pharm Co Revenue
- Kyung Nam Pharm Co Net Income
- Kyung Nam Pharm Co P/E
- Kyung Nam Pharm Co P/S
- Kyung Nam Pharm Co EBIT
- Kyung Nam Pharm Co Dividend
- Kyung Nam Pharm Co Stocks
- Kyung Nam Pharm Co Market capitalization
- Kyung Nam Pharm Co Debt
- Kyung Nam Pharm Co Liabilities
- Kyung Nam Pharm Co Equity
- Kyung Nam Pharm Co AAQS
- Kyung Nam Pharm Co Employees
- Kyung Nam Pharm Co ROE
- Kyung Nam Pharm Co ROA
- Kyung Nam Pharm Co ROCE